PHARMACOVIGILANCE STUDY OF ANTIHYPERTENSIVE DRUGS AT A TERTIARY CARE CENTER AND MEDICAL COLLEGE

Dr. Snehal Chavan, Dr. Alimuddin Shaikh*, Dr. Bhakti Chandekar and Dr. Deepak S. Bhosle

ABSTRACT

Introduction: According to WHO’s definition an Adverse Drug Reaction (ADR) is a response to a drug that is noxious and unintended and occurs at doses normally used in human for the prophylaxis, diagnosis, and treatment of disease, or for modification of physiological function. Adverse drug reactions (ADRs) are considered among the leading causes of morbidity and mortality if not addressed in time. Around 6% of hospital admissions are estimated to be due to ADRs and about 6-15% of hospitalized patients experience a serious ADRs. Hence, there is a need to monitor the safety profile of all the medications on continuous basis and to review their therapeutic rationale in case of chronic ailments such as hypertension. So, this study is planned “pharmacovigilance study of antihypertensive drugs at a tertiary care center and medical college” at MGM medical college Aurangabad, Maharashtra. Methods: An open labelled, non-comparative, observational study to monitor ADRs associated with antihypertensive medications at MGM Medical college, Aurangabad. Study was conducted in department Of Pharmacology, Pharmacovigilance Cell, MGM Medical College, Aurangabad. This study was completed in six months. Results: A total of 221 ADRs were reported in 1080 patients. The gender distribution among the patients, who experienced ADRs are mentioned in table below. In our study 119 males and 102 females had ADR. Our study found that Beta-blockers were most frequently associated with Adverse drug reactions followed by calcium channel blocker, angiotensin-converting enzyme inhibitors and Diuretics. Conclusion: The above study would be useful for the physicians in rational selection of drug therapy for treatment of hypertensive patients. Also Adverse drug reactions can be minimized with the evolving knowledge about the use of drugs judiciously.

Keywords: .